新辅助阿昔替尼对局限性晚期非转移性肾细胞癌患者人体测量参数的影响
基于单机构单臂临床试验,24例经活检证实的局限性晚期非转移性透明细胞肾细胞癌患者接受阿昔替尼口服最长12周后行肾切除术。23例可评估患者中19例(82.6%)体重下降,中位体重减少4.5 kg(P<.001),骨骼肌中位减少2.9 cm²/m²(P<.001),皮下脂肪中位减少1.0 cm²/m²(P=.043)。基线肌少症患者对新辅助阿昔替尼的缓解率 tended to lower。
要点
- 新辅助阿昔替尼治疗与骨骼肌和皮下脂肪减少及体重下降相关。
- 19例(82.6%)患者体重下降,中位体重减少4.5 kg(P<.001)。
- 基线肌少症患者部分缓解率14.3%(1/7)vs 无基线肌少症62.5%(10/16),P=.069。
核心结论
- 新辅助阿昔替尼导致骨骼肌和皮下脂肪组织减少以及体重下降。
- 基线肌少症患者对新辅助阿昔替尼的缓解率倾向于较低。
研究设计与样本
- 单机构、单臂临床试验,纳入24例经活检证实的局限性晚期非转移性透明细胞肾细胞癌患者。
- 患者口服阿昔替尼最长12周,在治疗开始前、治疗7周后及治疗12周完成时行计算机断层扫描,随后行肾切除术。
主要发现
- 23例患者有完整影像资料可供评估,其中19例(82.6%)体重下降,中位体重减少4.5 kg(P<.001)。
- 治疗前7例(30.4%)存在肌少症,治疗期间新增5例(21.7%)发生肌少症。
- 骨骼肌中位减少2.9 cm²/m²(P<.001),内脏脂肪组织中位减少4.9 cm²/m²(P=.132),皮下脂肪组织中位减少1.0 cm²/m²(P=.043)。
- 无基线肌少症的16例患者中10例(62.5%)达到部分缓解,而基线治疗前肌少症的7例患者中仅1例(14.3%)达到部分缓解(P=.069)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the effect that neoadjuvant axitinib for the treatment of localized renal cell carcinoma has on body compartment composition. MATERIALS AND METHODS: The study was based on a single-institution, single-arm clinical trial that enrolled 24 patients with locally advanced non-metastatic biopsy-proven clear cell renal cell carcinoma. Patients received axitinib orally for up to 12 weeks. Computed tomography scans were completed before the start of treatment, after 7 weeks of treatment and at the completion of 12 weeks of treatment. Patients underwent nephrectomy after axitinib treatment. The primary outcome of the current study was change in body compartment composition. Secondary outcomes included development of new-onset sarcopenia and changes in body weight. RESULTS: A total of 23 patients had a complete set of imaging for evaluation, of which 19 (82.6%) lost weight. Median weight loss was 4.5 kg (P <.001). Seven patients (30.4%) had sarcopenia before treatment, with an additional 5 (21.7%) developing sarcopenia during treatment. Median decrease in skeletal muscle was 2.9 cm2/m2 (P <.001), visceral adipose tissue was 4.9 cm2/m2 (P = .132), and subcutaneous adipose tissue was 1.0 cm2/m2 (P = .043). Ten of the 16 patients (62.5%) without baseline sarcopenia achieved a partial response, whereas only 1 of the 7 patients (14.3%) with baseline pretreatment sarcopenia achieved a partial response (P = .069). CONCLUSION: Neoadjuvant axitinib resulted in a decrease in skeletal muscle and subcutaneous adipose tissue, as well as weight loss. Patients with baseline sarcopenia tended to have a lower response rate to neoadjuvant axitinib.
引用
- Chéry L, Borregales LD, Fellman B, et al. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology. 2017. PMID: 28705573. doi:10.1016/j.urology.2017.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。